Location: Biologics Development Module
Project Number: 3022-32000-026-013-S
Project Type: Non-Assistance Cooperative Agreement
Start Date: Aug 1, 2024
End Date: Jul 31, 2026
Objective:
This project seeks to expand a repertoire of expression of FMDV VLPs constructs, for optimization of scale up production. Collaborators will provide expertise on VLP expression methods, antigen design, molecular methods, and purification methods. Specific objectives include:
1. Production of DNA plasmids capable of expressing intact FMDV VLPs in multiple expression systems, including yeast, mamalian cells, bacteria, and/or baculovirus.
2. Support optimization of expression process and scaling up in partnership with Industry.
3. Evaluate the immunogenic properties of expressed and purified VLPs.
Approach:
Parental and mosaic VLP plasmid cassettes has been produced by ARS and tested in the laboratory for virus capsid proteins expression. Optimization of the VLP release processes and for yeast-inactivation have been preliminary bench tested. The work outlined in this proposal will use ARS expertise in bioinformatics, genetic engineering, immunology and vaccine development to deliver FMDV VLP with potential for broadly protective vaccines, which could be a better product profile for FMD control tool in disease-free and FMD endemic countries. Preliminary discussion to engage collaborative work with Gingko is undergoing. This industrial partner will bring expertise on scaling up of processes and to generate VLP for animal studies as outlines in objectives above.
